BMC Rheumatology最新文献

筛选
英文 中文
Antimelanoma differentiation-associated gene 5 (anti-MDA5) antibody-positive dermatomyositis: clinical features and outcomes in a racially diverse patient cohort. 抗黑色素瘤分化相关基因5(抗mda5)抗体阳性的皮肌炎:不同种族患者队列的临床特征和结果
IF 2.1
BMC Rheumatology Pub Date : 2025-01-09 DOI: 10.1186/s41927-025-00455-5
Sai K Koyoda, Fatema Ezzy, Dawn Wahezi, Anand Kumthekar, Xianhong Xie, Clement E Tagoe, Bibi Ayesha
{"title":"Antimelanoma differentiation-associated gene 5 (anti-MDA5) antibody-positive dermatomyositis: clinical features and outcomes in a racially diverse patient cohort.","authors":"Sai K Koyoda, Fatema Ezzy, Dawn Wahezi, Anand Kumthekar, Xianhong Xie, Clement E Tagoe, Bibi Ayesha","doi":"10.1186/s41927-025-00455-5","DOIUrl":"10.1186/s41927-025-00455-5","url":null,"abstract":"<p><strong>Background: </strong>The anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody-positive dermatomyositis is known for its association with rapidly progressive interstitial lung disease (RP-ILD) and ulcerative skin lesions, often presenting with or without muscle involvement. The aim of this study was to identify distinct clinical and laboratory features that could be used to evaluate disease progression in an ethnically diverse cohort of anti-MDA5 dermatomyositis patients at a U.S. academic center.</p><p><strong>Methods: </strong>A retrospective chart review was conducted on dermatomyositis patients hospitalized at our institution between January 2014 and June 2023. The data were analyzed via Fischer's exact test and a t test.</p><p><strong>Results: </strong>Among the 195 dermatomyositis patients reviewed, 22 tested positive for the MDA5 antibody, comprising of thirteen adults and nine pediatric patients. Myositis was significantly more common in pediatric patients than in adult patients (p = 0.002). RP-ILD was more frequently observed in adult patients of African ancestry (including both Black Hispanic and Black non-Hispanic individuals) (p = 0.04). There was a significant association noted between Raynaud's phenomenon and ILD (p = 0.02). The overall mortality rate of 13.6% was more favorable than the previously reported rates of 40-60%.</p><p><strong>Conclusion: </strong>This study enhances our understanding of the disease by emphasizing potential racial and demographic variations, as well as delineating the similarities and differences between adult and pediatric populations.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"5"},"PeriodicalIF":2.1,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11715331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142944719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world effectiveness of intravenous belimumab in adults with systemic lupus erythematosus: results of the observational OBSErve study in the Russian Federation. 静脉注射贝利单抗治疗成人系统性红斑狼疮的实际疗效:俄罗斯联邦观察性研究的结果。
IF 2.1
BMC Rheumatology Pub Date : 2025-01-08 DOI: 10.1186/s41927-024-00452-0
Alexander Mikhailovich Lila, Elena Aleksandrovna Aseeva, Alyona Igorevna Zagrebneva, Irina Borisovna Vinogradova, Ruzana Ramilovna Samigullina, Munther Khamashta, Tamer Elfishawy, Lindsey Teichman, Debora Dos Santos, Juliana Queiroz, Larisa Alexandrovna Kniazeva, Saeed Noibi
{"title":"Real-world effectiveness of intravenous belimumab in adults with systemic lupus erythematosus: results of the observational OBSErve study in the Russian Federation.","authors":"Alexander Mikhailovich Lila, Elena Aleksandrovna Aseeva, Alyona Igorevna Zagrebneva, Irina Borisovna Vinogradova, Ruzana Ramilovna Samigullina, Munther Khamashta, Tamer Elfishawy, Lindsey Teichman, Debora Dos Santos, Juliana Queiroz, Larisa Alexandrovna Kniazeva, Saeed Noibi","doi":"10.1186/s41927-024-00452-0","DOIUrl":"10.1186/s41927-024-00452-0","url":null,"abstract":"<p><strong>Background: </strong>The real-world effectiveness of intravenous (IV) belimumab in treating systemic lupus erythematosus (SLE) has been demonstrated in various countries through the OBSErve (evaluation Of use of Belimumab in clinical practice SEttings) program. Here we describe the clinical effectiveness of IV belimumab for treating SLE in real-world clinical practice in the Russian Federation.</p><p><strong>Methods: </strong>In the retrospective, observational OBSErve Russia study (GSK Study 215349), eligible physicians enrolled adults with SLE receiving IV belimumab as part of their standard care. De-identified data were collected from patient medical records from September 2021 to March 2022. The primary outcome was the physician-assessed overall clinical response at 6 months post-index versus index (belimumab initiation) among patients receiving belimumab for ≥6 months. Other endpoints included change in Safety of Estrogens in Lupus Erythematosus National Assessment - SLE Disease Activity Index (SELENA-SLEDAI) score and glucocorticoid use.</p><p><strong>Results: </strong>Overall, 59 patients initiated IV belimumab, mainly due to the previous regimen not being effective and to decrease glucocorticoid use (76.3% each); 15.3% of patients started belimumab within the first year of SLE diagnosis. Only 13.6% of patients discontinued belimumab within the first 6 months, mainly due to loss to follow-up and loss of insurance/reimbursement. At 6 months post-index, among patients who completed ≥6 months of belimumab therapy (full analysis set, n = 53), 90.6% and 60.4% had an overall clinical improvement of ≥20% and ≥50%, respectively. Mean (standard deviation, SD) change in SELENA-SLEDAI score from index to 6 months post-index was -5.9 (4.3). Mean (SD) glucocorticoid dose decreased from 12.2 (7.3) mg/day at index to 8.6 (5.1) mg/day at 6 months post-index (n = 50).</p><p><strong>Conclusions: </strong>Patients with SLE receiving IV belimumab for 6 months in real-world settings in the Russian Federation experienced overall clinical improvements and reductions in glucocorticoid use, which is an important long-term strategy of SLE treatment.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"4"},"PeriodicalIF":2.1,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11708191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142944731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is middle East pain syndrome (MEPS) a variant of fibromyalgia syndrome or a distinct disease? 中东疼痛综合征(MEPS)是纤维肌痛综合征的一种变体还是一种独特的疾病?
IF 2.1
BMC Rheumatology Pub Date : 2025-01-08 DOI: 10.1186/s41927-024-00428-0
Mona H Elhamamy, Adel A Elbeialy, Maha S Mohamed, Sabah E Abdelraheem, Hala M Elzomor
{"title":"Is middle East pain syndrome (MEPS) a variant of fibromyalgia syndrome or a distinct disease?","authors":"Mona H Elhamamy, Adel A Elbeialy, Maha S Mohamed, Sabah E Abdelraheem, Hala M Elzomor","doi":"10.1186/s41927-024-00428-0","DOIUrl":"https://doi.org/10.1186/s41927-024-00428-0","url":null,"abstract":"<p><strong>Background: </strong>Fibromyalgia Syndrome (FMS) is a chronic disabling musculoskeletal condition of unknown aetiology characterized by generalized musculoskeletal pain, extreme fatigue, mood disturbance, impaired cognition, and lack of refreshing sleep. Middle East pain syndrome (MEPS) is a newly described pollution-induced syndrome of hyperparathyroidism and fibromyalgia mimicking rheumatoid arthritis, characterized by the radiological presence of spur-like excrescences in terminal phalanges. This study aimed to explore the inflammatory nature of Middle East pain and Fibromyalgia syndromes.</p><p><strong>Methods: </strong>Eighty primary fibromyalgia patients were included in this study. They were divided into two groups, group [1] 1 of 40 FMS patients with low vitamin D levels and secondary hyperparathyroidism, which were diagnosed as MEPS, and group [2] of 40 primary FMS patients. They were subjected to full medical history taking, clinical examination and laboratory assessment including serum IL-17 by enzyme-linked immunosorbent assay technique, as well as assessment of Madrid Sonographic Enthesitis Index (MASEI) using musculoskeletal ultrasound and nailfold capillaroscopic pattern assessment. Plain X-ray films for hands were done on all patients.</p><p><strong>Results: </strong>There was a statistically significant elevation of serum IL17 in the MEPS group (median = 58.3 ng/L) compared to the FMS group (median = 45.7 ng/L) as the p-value is < 0.05. Capillaroscopic examination revealed a statistically significant difference between MEPS and FMS groups regarding angiogenesis as the p-value is < 0.05. The ultrasonographic examination also showed a statistically significant difference between MEPS and FMS groups as regards MASEI score as the p-value is < 0.05. Hands X-rays evidenced the exclusive existence of tuft spur-like excrescences in MEPS patients only.</p><p><strong>Conclusion: </strong>Elevated IL-17 levels, non-scleroderma pattern capillaroscopic and enthesopathy findings in both MEPS and FMS patients are strongly supportive that inflammatory mechanisms participate in the pathogenesis of both diseases. The significant increase of these findings in MEPS than FMS patients as well as the presence of hand tufts spur-like excrescences, confirm that the newly discovered MEPS is a different disease although it involves fibromyalgia symptoms and signs.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"3"},"PeriodicalIF":2.1,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11708104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142944728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing the relation between systemic lupus erythematosus and metabolic syndrome in Syria: a cross-sectional study. 评估叙利亚系统性红斑狼疮和代谢综合征之间的关系:一项横断面研究。
IF 2.1
BMC Rheumatology Pub Date : 2025-01-03 DOI: 10.1186/s41927-024-00453-z
Noura Mallouhi, Ahmad Nabil Alhouri, Naram Khalayli, Hasan Nabil Alhouri, Mayssoun Kudsi, Younes Kabalan
{"title":"Assessing the relation between systemic lupus erythematosus and metabolic syndrome in Syria: a cross-sectional study.","authors":"Noura Mallouhi, Ahmad Nabil Alhouri, Naram Khalayli, Hasan Nabil Alhouri, Mayssoun Kudsi, Younes Kabalan","doi":"10.1186/s41927-024-00453-z","DOIUrl":"10.1186/s41927-024-00453-z","url":null,"abstract":"<p><strong>Background: </strong>Systemic Lupus Erythematosus (SLE) affects all organ systems. As a result, fat intake and sedentary life are evident in the modern world. The prevalence of metabolic syndrome, with its components, increased, leading to increased mortality. We aimed to investigate the prevalence of metabolic syndrome in SLE and its relationship with disease activity.</p><p><strong>Methods: </strong>A cross-sectional study was conducted on 70 SLE patients at Al Mouwasat University Hospitals in Damascus, Syria, between November 2021 and November 2022. The patients were divided into two groups based on the presence or absence of metabolic syndrome. The SLE Disease Activity Index (SLEDAI) was assessed in each group and compared with different disease parameters.</p><p><strong>Results: </strong>Out of the 70 patients, 65 were females. The mean age was 32.19 ± 7.15 years, and the mean disease duration was 4.4 ± 2.96 years. Metabolic syndrome was found in 32 patients (45.7%). Metabolic syndrome in SLE patients was associated with a higher disease activity index, older age, delayed age at first diagnosis, longer disease duration, higher frequency of renal involvement, and use of cyclophosphamide.</p><p><strong>Conclusion: </strong>Our study highlights the importance of evaluating and treating metabolic syndrome and its components in patients with SLE, as it may play a role in controlling disease activity. We recommend conducting larger studies in the future to overcome the limitations of this research, such as including a larger number of patients, conducting multicenter studies to generalize the results, and including a healthy control group.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"2"},"PeriodicalIF":2.1,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11697729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between red blood cell distribution width and genetic risk in patients with rheumatoid arthritis: a prospective cohort study and Mendelian randomization analysis. 类风湿关节炎患者红细胞分布宽度与遗传风险的关系:一项前瞻性队列研究和孟德尔随机化分析
IF 2.1
BMC Rheumatology Pub Date : 2025-01-02 DOI: 10.1186/s41927-024-00451-1
Mingyang Chen, Jing Lei, Zhenqiu Liu, Renjia Zhao, Yanfeng Jiang, Kelin Xu, Tiejun Zhang, Chen Suo, Xingdong Chen
{"title":"Association between red blood cell distribution width and genetic risk in patients with rheumatoid arthritis: a prospective cohort study and Mendelian randomization analysis.","authors":"Mingyang Chen, Jing Lei, Zhenqiu Liu, Renjia Zhao, Yanfeng Jiang, Kelin Xu, Tiejun Zhang, Chen Suo, Xingdong Chen","doi":"10.1186/s41927-024-00451-1","DOIUrl":"10.1186/s41927-024-00451-1","url":null,"abstract":"<p><strong>Objective: </strong>Elevated red blood cell distribution width (RDW) is associated with increased risk of rheumatoid arthritis (RA), but the potential interactions of RDW with genetic risk of incident RA remain unclear. This study aimed to investigate the associations between RDW, genetics, and the risk of developing RA.</p><p><strong>Methods: </strong>We analysed data from 145,025 healthy participants at baseline in the UK Biobank. The endpoint was diagnosed rheumatoid arthritis (ICD-10 codes M05 and M06). Using previously reported results, we constructed a polygenic risk score for RA to evaluate the joint effects of RDW and RA-related genetic risk. Two-sample mendelian randomization and bayesian colocalization were used to infer the causal relation between them.</p><p><strong>Results: </strong>A total of 675 patients with RA were enrolled and had a median followed up of 5.1 years, with an incidence rate of 0.57/1000 person-years. The hazard ratio of RA was 1.89 (95% CI: 1.45, 2.47) in highest RDW quartile group compared with the lowest RDW quartile group. Individuals within the top quintile of PRS showed a significantly high risk of RA. Moreover, Participants with high genetic risk and those in highest RDW group exhibited a significantly elevated hazard ratio (7.67, 95% CI: 3.98, 14.81), as opposed to participants with low genetic risk and those in lowest RDW group. Interactions between PRS and RDW on the multiplicative and additive scale were observed. Mendelian randomization provided suggestive evidence of a bi-directional causal relationship between RDW and RA. Loci near IL6R, IL1RN, FADS1/FADS2, UBE2L3 and HELZ2 showed colocalization.</p><p><strong>Conclusion: </strong>Increased RDW is associated with elevated risk of incident RA especially in the high genetic risk populations, but only suggestive evidence supports a causal relationship between them.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"1"},"PeriodicalIF":2.1,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142913615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of hematological markers as prognostic tools in rheumatoid arthritis. 血液学指标作为类风湿关节炎预后工具的评价。
IF 2.1
BMC Rheumatology Pub Date : 2024-12-26 DOI: 10.1186/s41927-024-00444-0
Maryam Masoumi, Maryam Bozorgi, Zahra Nourmohammadi, Mohammad Javad Mousavi, Aref Shariati, Jafar Karami
{"title":"Evaluation of hematological markers as prognostic tools in rheumatoid arthritis.","authors":"Maryam Masoumi, Maryam Bozorgi, Zahra Nourmohammadi, Mohammad Javad Mousavi, Aref Shariati, Jafar Karami","doi":"10.1186/s41927-024-00444-0","DOIUrl":"10.1186/s41927-024-00444-0","url":null,"abstract":"<p><strong>Background: </strong>Reducing inflammation is central to the management of RA. However, commonly used markers such as CRP and ESR, along with the DAS-28 score, have shown limitations. Hematologic indices, such as platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), and neutrophil-lymphocyte ratio (NLR), show potential as reliable indicators of inflammation in RA. This study evaluates these markers across different RA activity levels to identify effective biomarkers for distinguishing active RA from remission.</p><p><strong>Materials and methods: </strong>305 RA patients were enrolled in our study, diagnosed by ACR/EULAR 2010 criteria, and divided into four groups according to the DAS28-ESR score. 8 ml of blood were taken for a CBC test and serological tests such as rheumatoid factor (RF), anticyclic citrullinated peptide antibodies (anti-CCP), anti-nuclear antibodies (ANA), and C-reactive protein (CRP). Platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), and neutrophil-lymphocyte ratio (NLR) were assessed as potential markers of inflammation.</p><p><strong>Results: </strong>The mean age of RA patients was 51.7 years and a disease duration of 56.7 months. Significant differences in tender and swollen joints were observed between RA groups. Laboratory findings revealed higher CRP and ESR in active RA patients, while hemoglobin, hematocrit, and lymphocyte counts were higher in remission group. ROC analysis showed ESR, CRP, NLR, and PLR as potential markers for distinguishing active from remission RA, with ESR demonstrating the highest diagnostic accuracy. LMR could not differentiate between active and inactive forms of RA disease.</p><p><strong>Conclusion: </strong>The NLR and PLR markers were significantly correlated with traditional inflammatory markers like CRP and ESR. These novel markers could be useful tools for evaluating RA activity, offering a cost-effective alternative to imaging techniques. Further research is needed to confirm their clinical utility.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"8 1","pages":"75"},"PeriodicalIF":2.1,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11670421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The association between composite dietary antioxidant index and rheumatoid arthritis: evidence from NHANES 2001-2020. 膳食复合抗氧化指数与类风湿关节炎之间的关系:来自NHANES 2001-2020的证据
IF 2.1
BMC Rheumatology Pub Date : 2024-12-24 DOI: 10.1186/s41927-024-00447-x
Guangbin Ma, Shulin Zhang, Yiyan Luo, Chengcheng Zhang, Weina Xu, Liyan Wang
{"title":"The association between composite dietary antioxidant index and rheumatoid arthritis: evidence from NHANES 2001-2020.","authors":"Guangbin Ma, Shulin Zhang, Yiyan Luo, Chengcheng Zhang, Weina Xu, Liyan Wang","doi":"10.1186/s41927-024-00447-x","DOIUrl":"10.1186/s41927-024-00447-x","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to investigate the relationship between the composite dietary antioxidant index (CDAI) and rheumatoid arthritis (RA) using data from the National Health and Nutrition Examination Survey (NHANES) spanning from 2001 to 2020.</p><p><strong>Methods: </strong>CDAI is based on the intake of vitamins A, C, E, manganese, selenium, and zinc from the diet. RA patients were identified through questionnaire responses. Weighted multivariate regression analysis was employed to examine the association between CDAI and RA. Additionally, restricted cubic splines were utilized to assess potential non-linear relationships. Subgroup analyses were used to explore whether the relationship between CDAI and RA remained consistent across subgroups (e.g., sex, age, smoking status, etc.). We also used interaction terms to assess whether these subgroup variables influence the relationship between CDAI and RA risk. Finally, we also performed sensitivity analyses to assess the robustness of the main findings after excluding patients with a history of diabetes.</p><p><strong>Results: </strong>The study included a total of 11,266 patients. After adjusting for all covariates, the multivariate logistic regression analysis showed that each unit increase in CDAI was associated with a 4% reduction in the odds of RA (odds ratio = 0.96, 95% confidence interval = 0.94-0.99). The incidence of RA was found to decrease as CDAI levels increased (P for trend < 0.05). In the restricted cubic spline analysis, a linear relationship between CDAI and RA was observed. Subgroup analyses and interactions demonstrated that the negative association between CDAI and RA was consistent across all subgroups and was influenced by smoking.</p><p><strong>Conclusion: </strong>This study indicates a negative correlation between CDAI and RA, suggesting that CDAI may serve as a valuable and convenient marker for reducing the risk of RA in US adults.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"8 1","pages":"74"},"PeriodicalIF":2.1,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11667885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utility of the GerdQ questionnaire in detecting gastroesophageal symptoms with RA patients. GerdQ问卷在RA患者胃食管症状检测中的应用
IF 2.1
BMC Rheumatology Pub Date : 2024-12-23 DOI: 10.1186/s41927-024-00442-2
Yuji Nozaki, Kazuya Kishimoto, Daisuke Tomita, Tetsu Itami, Chisato Ashida, Koji Kinoshita, Itaru Matsumura
{"title":"Utility of the GerdQ questionnaire in detecting gastroesophageal symptoms with RA patients.","authors":"Yuji Nozaki, Kazuya Kishimoto, Daisuke Tomita, Tetsu Itami, Chisato Ashida, Koji Kinoshita, Itaru Matsumura","doi":"10.1186/s41927-024-00442-2","DOIUrl":"10.1186/s41927-024-00442-2","url":null,"abstract":"<p><strong>Objective: </strong>Rheumatoid arthritis (RA) affects multiple organ systems, including the esophagus. Moreover, one of the major side effects of methotrexate (MTX) is gastrointestinal disorders, which are said to affect medication adherence. We investigated the rate of MTX use, dosage, and the use of glucocorticoids (GCs) and oral non-steroidal anti-inflammatory drugs (NSAIDs) in relation to gastroesophageal (GE) symptoms, and whether they influence RA disease activity.</p><p><strong>Methods: </strong>This study utilized the GerdQ questionnaire to analyze the influence of GE symptoms on RA disease activity and medication adherence. A total of 558 RA patients participated. On the day of the GerdQ questionnaire, data on age, gender, disease duration, RA disease activity, lab results, and lifestyle factors such as smoking history and alcohol consumption were recorded. Detailed drug information on conventional synthetic DMARDs (csDMARDs), biologic/targeted synthetic DMARDs (b/tsDMARDs), glucocorticoids, and NSAIDs were extracted from medical records. Propensity score matching adjusted patient background characteristics.</p><p><strong>Results: </strong>Before matching, patients with moderate to high disease activity had higher GE symptoms (12.7% vs. 25.6%). After matching, higher GerdQ scores were correlated with increased tender joint counts 28 (TJC28) and worse visual analog scale (VAS) scores. Oral MTX usage was similar, but the dosage was significantly lower in the group with higher GerdQ scores (51.4% vs. 50.8% and 7.7 ± 2.4 mg/wks vs. 6.5 ± 2.6 mg/wks, p < 0.05*).</p><p><strong>Conclusions: </strong>GE symptoms significantly impact MTX treatment and patient-reported outcomes such as TJC28 and VAS in RA disease activity, highlighting their importance in RA treatment strategies. For clinicians, the study's results will emphasize the importance of monitoring and managing GE symptoms in RA patients, particularly those on MTX therapy. Furthermore, the data could provide a basis for future studies that explore targeted interventions to mitigate GE symptoms and enhance medication adherence, potentially improving RA outcomes.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"8 1","pages":"73"},"PeriodicalIF":2.1,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of C-reactive protein and genetic predisposition in the risk of psoriasis: results from a national prospective cohort. c反应蛋白和遗传易感性在牛皮癣风险中的作用:来自全国前瞻性队列的结果。
IF 2.1
BMC Rheumatology Pub Date : 2024-12-21 DOI: 10.1186/s41927-024-00450-2
Huarun Li, Haobin Zhang, Xiangyue Zhao, Jinping Huang, Junguo Zhang, Zhaoyan Liu, Ju Wen, Si Qin
{"title":"The role of C-reactive protein and genetic predisposition in the risk of psoriasis: results from a national prospective cohort.","authors":"Huarun Li, Haobin Zhang, Xiangyue Zhao, Jinping Huang, Junguo Zhang, Zhaoyan Liu, Ju Wen, Si Qin","doi":"10.1186/s41927-024-00450-2","DOIUrl":"10.1186/s41927-024-00450-2","url":null,"abstract":"<p><strong>Background: </strong>Psoriasis is an immune-mediated chronic inflammatory disease associated with multiple factors. To evaluate the extent to which C-reactive protein (CRP) and genetic predisposition affect the incidence of psoriasis.</p><p><strong>Methods: </strong>The cohort study retrieved 420,040 participants without psoriasis at baseline from the UK Biobank. Serum CRP was categorized into two levels: < 2 mg/L (normal) and ≥ 2 mg/L (elevated). The polygenic risk score (PRS) was used to estimate genetic predisposition, and was characterized as low, moderate and high PRS. The possible interaction and joint associations between CRP and PRS were assessed using Cox proportional hazards models.</p><p><strong>Results: </strong>Participants with high CRP levels had an increased risk of incident psoriasis compared to those with low CRP levels (HR: 1.26, 95% CI: 1.18-1.34). Participants with high CRP levels and high PRS had the highest risk of incident psoriasis [2.24 (95% CI: 2.01, 2.49)], compared with those had low CRP levels and low PRS. Significant additive and multiplicative interaction were found between CRP and PRS in relation to the incidence of psoriasis.</p><p><strong>Conclusions: </strong>Our results suggest that higher CRP concentration may be associated with higher psoriasis incidence, with a more pronounced association observed in individuals with high PRS for psoriasis. So, clinicians should be aware that the risk of incident psoriasis may increase in general population with high CRP levels and high PRS, so that early investigation and intervention can be initiated.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"8 1","pages":"72"},"PeriodicalIF":2.1,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11662795/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between serum urate levels and all-cause mortality, cardiovascular and renal outcomes among gout patients in Singapore. 新加坡痛风患者血清尿酸水平与全因死亡率、心血管和肾脏预后之间的关系
IF 2.1
BMC Rheumatology Pub Date : 2024-12-20 DOI: 10.1186/s41927-024-00449-9
Moses Yidong Lim, Weixiang Lian, Hwee Pin Phua, Htet Lin Htun, Kok Ooi Kong, Ling Li Foo, Teo Min-Li Claire, Wei-Yen Lim
{"title":"Association between serum urate levels and all-cause mortality, cardiovascular and renal outcomes among gout patients in Singapore.","authors":"Moses Yidong Lim, Weixiang Lian, Hwee Pin Phua, Htet Lin Htun, Kok Ooi Kong, Ling Li Foo, Teo Min-Li Claire, Wei-Yen Lim","doi":"10.1186/s41927-024-00449-9","DOIUrl":"10.1186/s41927-024-00449-9","url":null,"abstract":"<p><strong>Objectives: </strong>We investigated the longitudinal association between Serum Urate (SU) level and Acute Myocardial Infarction (AMI), Stroke, End Stage Renal Failure (ESRF) and all-cause mortality.</p><p><strong>Design: </strong>We conducted a retrospective hospital-based cohort study of individuals with gout managed in specialist outpatient clinics. Cox proportional hazards regression was used to estimate HR and 95% CI, with adjustments for potential confounders. Where the proportional hazard assumption was violated, stratified Cox regression was applied instead.</p><p><strong>Setting: </strong>An acute care tertiary hospital in Singapore.</p><p><strong>Participants: </strong>Individuals with a first gout diagnosis between 2007-2017, identified through (i) primary discharge diagnosis, (ii) diagnosis from the Rheumatology SOC (iii) patient history of a clinical encounter at the Rheumatology SOC plus use of urate-lowering therapy/colchicine.</p><p><strong>Main outcome measures: </strong>All-cause mortality, AMI, Stroke and ESRF ascertained through data linkage with the National Registry of Diseases Office.</p><p><strong>Results: </strong>The final cohort comprised 2,866 individuals. Post follow-up, there were 800 deaths and 362, 218 and 191 occurrences of AMI, ESRF and stroke respectively. Compared to the reference (second-lowest) SU quartile, being in the highest SU quartile was associated with a significantly increased hazard for mortality (HR:1.66, 95% CI:1.36-2.03), incident ESRF (HR:3.02, 95% CI:2.00-4.56), and increased hazard for incident AMI (HR:1.42, 95% CI:1.06-1.91). The p-trend for all 3 outcomes was significant. No significant association was found between SU quartile and hazard for incident stroke.</p><p><strong>Conclusions: </strong>This study found that individuals with gout managed at SOC who had higher baseline SU levels had an increased hazard for all-cause mortality, ESRF, and AMI.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"8 1","pages":"71"},"PeriodicalIF":2.1,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11662592/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信